Financial联社Nov. 8th News (Reporter He Fan) At today's earnings conference, Shandong Lukang Pharmaceutical (600789.SH) new synthetic biotechnology material product FT606 has attracted much attention.

Some investors asked, "Can the FT606 project be put into production on schedule this year?" "When is the trial production scheduled for the new FT606 project, and when will it be officially put into production?" "When can it be launched into the market?"

However, as of the end of the earnings conference, the company did not directly respond to questions about production time, economic benefits, etc.

Shandong Lukang Pharmaceutical's 2022 interim report shows that the company's new synthetic biotechnology material product FT606 developed in partnership with the Qingdao Institute of Bioenergy under the Chinese Academy of Sciences signed a technology transfer agreement in the second half of the year and started the construction of a thousand-ton verification plant.

Chairman of Shandong Lukang Pharmaceutical, Peng Xin, stated that FT606 plasticizer belongs to bio-based plasticizer, which can be used in areas such as food packaging, children's toys, medical supplies, and plastic products closely in contact with the human body. At the same time, he stated that the FT606 project is progressing with full force according to the planned schedule. Independent director Feng Liliang expressed that trans-Uconic acid has broad application prospects in agricultural nematode control.

According to industrial and commercial information, Shandong Lukang Pharmaceutical's FT606 project completed mechanical and electrical installation and automation engineering tendering on September 29th, and is currently carrying out the procurement of galvanized steel pipes, angle steel, and channel steel.

In addition, regarding the decline in Shandong Lukang Pharmaceutical's Q3 performance - achieving a total revenue of 1.387 billion yuan, a year-on-year decrease of 10.24%, achieving a net profit attributable to the parent company of 47.0961 million yuan, a year-on-year decrease of 23.01% - the company's CFO Zhang Jing responded to the Financial联社 reporter that, influenced by the market environment, the pharmaceutical industry was in the traditional off-season in the third quarter. The company will increase the refinement of marketing management efforts to enhance the sales volume and market share of Shandong Lukang products.

At today's earnings conference, there was a brief "incident", with some investors complaining about the lack of interaction with the directors. In response to similar questions, the company directors all replied that "the company will enhance communication and actively address investors' concerns in the future."